Boston Scientific Platinum Chromium Stent System ™ ion shows the performance analysis of Perseus and TAXUS ATLAS clinical trial data

ION stent system offers innovative RPTC alloy stent design for greater strength, improved deliverability and visibility. The stent is designed to better fit leg slim, slight decrease, and lesion coverage and uniform distribution of the drug. The delivery system of advanced low profile facilitates the precise delivery of the stent through difficult lesions.United States, the stent ION system is an experimental device, limited by law for the experimental use and not available for sale.

Dioxins are mainly produced from the incineration of municipal and medical waste, including some plastics. Dioxins enter the food chain when the emissions into the atmosphere are deposited on farmland, where cattle graze e. Fish also ingest dioxins and related pollutants from contaminated water. When humans take in dioxins mainly through meat, dairy products toxin, fish and seafood is deposited in adipose tissue, the natural elimination is very slow. Human exposure is generally a low daily dose, which has been linked to a possible violation of the immune system and organ development.

Boston Scientific Corporation today announced results of a pooled patient-level analysis of the Perseus and TAXUS ATLAS clinical trial data, which shows the differences in the safety and efficacy of positive results the next generation of platinum chromium ions paclitaxel-eluting stent system than the currently available paclitaxel-TAXUS Liberte coronary stent system. The results were presented at the American College of Cardiology Annual Scientific Sessions by Dean Kereiakes, MD, medical director at the Hospital Heart and Vascular Center of Christ and the Lindner Research Center in Cincinnati, and principal investigator for the PERSEUS clinical program.

The study compared patients in pooled data from 2298 patients included in the PERSEUS and TAXUS ATLAS trial. Propensity score matching was performed to account for differences in the characteristics of patients and lesions between the groups, and clinical follow-up was conducted over 12 months. Results propensity matching of 1326 patients revealed that the ION stents reached significantly lower rate of MACE and TLF mainly by a reduction of myocardial infarction . Rate numerically lower but not statistically different from target vessel revascularization was also observed for the stent ION , supported by the late loss at nine months significantly lower .

‘While the ION and the TAXUS Liberte Stent using the same drug and polymer, the ION stent demonstrated significantly lower rate of major adverse cardiac events , target lesion failure and myocardial infarction in this case, analysis is nearly 2,300 patients, ‘said Dr. Kereiakes.’ This study shows that the composition of alloys, the stent design and leg thickness may influence the clinical and angiographic results after drug-eluting stents. ‘